Myelofibrosis Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2031
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Myelofibrosis Market Report Overview
The myelofibrosis market size was $2.39 billion across the 8MM in 2021 and will achieve a CAGR of more than 1% during 2021-2031. The approvals of several late-stage pipeline agents especially Vonjo and momelotinib and the continued strong performance of Jakafi/Jakavi in the first-line setting will drive market growth during the forecast period.
Myelofibrosis Market Outlook, 2021-2031 ($ Billion)
Buy the Full Report to Gain More Information on the Myelofibrosis Market Forecast
The myelofibrosis market research covers the 8MM (the US, France, Germany, Italy, Spain, China, Japan, and the UK) and provides a forecast model for the myelofibrosis market through 2031.
Market Size (2021) | $2.39 billion |
CAGR (2021-2031) | >1% |
Key Class of Drugs (5EU) | · JAK Inhibitors
· Antimetabolities · ESAs · Glucocorticoids · Immunomodulatory Agents |
Leading Players | · Novartis
· GSK · CTI · Zelgen · Abbvie |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Myelofibrosis Market Insights
The patent expiry of Jakafi/Jakavi is hampering the market growth. However, approvals of late-stage pipeline agents, including novel JAK inhibitors and targeted therapies, which will partially meet critical unmet clinical needs will propel the myelofibrosis market growth during the forecast period.
Myelofibrosis - Treatment Insights
- In the US, there are three approved therapies for myelofibrosis including Incyte’s Jakafi (ruxolitinib) (approved 2011), BMS’s Inrebic (fedratinib) (approved 2019), and CTI BioPharma’s Vonjo (pacritinib) (approved 2022).
- Vonjo and momelotinib are well-positioned to alleviate some of the unmet needs in MF, including providing improved treatment options for patients with low platelets and anemia respectively.
Buy the Full Report for More Myelofibrosis Treatment Insights
Myelofibrosis Market Segmentation by Class of Drugs
In 2021, the leading global drug class myelofibrosis market in 5EU was JAK Inhibitors.
The key classes of drugs in the 5EU myelofibrosis market are JAK Inhibitors, Antimetabolities, ESAs, Glucocorticoids, and Immunomodulatory Agents. JAK inhibitors are generally used in higher-risk patients.
Myelofibrosis Market Analysis by Class of Drugs, 2021 (%)
Buy the Full Report for More Drugs Insights into the 5EU myelofibrosis Market
Myelofibrosis Market - Competitive Landscape
A few of the leading players in the myelofibrosis market are:
- Novartis
- GSK
- CTI
- Zelgen
- Abbvie
Incyte was the first big pharma company to penetrate the MF market with its landmark approval of Jakafi/Jakavi in November 2011, becoming the first approved targeted agent for MF patients and subsequently achieving blockbuster status. Accordingly, Jakafi/Jakavi is one of Incyte’s most valuable assets, for which the commercial returns generated from the MF market share are still heavily relied upon by the company.
Myelofibrosis Market Analysis by Companies
Buy the Full Report for More Myelofibrosis Company Insights
Scope
- Understand the epidemiology, symptoms, diagnosis, and management of myelofibrosis, to get a better overview of the market.
- Annualized myelofibrosis market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2021 to 2031.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the myelofibrosis therapeutics market.
- Comprehensive data assessing emerging trends and mechanisms of action under development for myelofibrosis treatment. The most promising candidates in Phase III and Phase IIb development are profiled.
- Analysis of the current and future market competition in the global myelofibrosis therapeutics market.
- Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Key Highlights
Report deliverables include a PowerPoint report and Excel-based forecast model
Forecasts includes the 8MM
Forecasts covers from 2021-2031
GlobalData valued the myelofibrosis market in the 8MM at $2.39 billion and expects the market to increase to $2.89 billion by 2031
Incyte, GSK and CTI BioPharma are expected to take market-leading position in 2031
A moderate level of unmet need will remain for most myelofibrosis patient populations during the forecast period
The late-stage pipeline in myelofibrosis is robust and is likely to provide significant clinical benefit to many myelofibrosis patient populations, with fierce competition expected
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM myelofibrosis therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM myelofibrosis therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Acceleron Pharma
Bristol Myers Squibb
Constellation Pharmaceuticals
CTI BioPharma
Geron
GSK
Hangzhou Bangshun Pharmaceutical
Huadong Medicine
Impact Biomedicines
Incyte
Kartos Therapeutics
Morphosys
Novartis
Sierra Oncology
Suzhou Zelgen Pharmaceuticals
Table of Contents
Table
Figures
Frequently asked questions
-
What was the myelofibrosis market size across the 7MM in 2021?
The myelofibrosis market size across the 7MM was $2.39 billion in 2021.
-
What will the myelofibrosis market growth rate be during the forecast period?
The myelofibrosis market will achieve a CAGR of more than 1% during 2021-2031.
-
Which drug was the highest selling in the 5EU myelofibrosis market in 2021?
JAK inhibitors was the highest-selling drug in 2021.
-
Who are the leading players in the myelofibrosis market?
A few of the leading players in the myelofibrosis market are Novartis, GSK, CTI, Zelgen, Abbvie among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.